⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23886232 | 0.97 | GLA (0.65) | — | |
| SCHEMBL4350905 | 0.97 | CYP1A2 (0.61) | — | |
| SCHEMBL9131420 | 0.97 | CYP1A2 (0.61) | — | |
| SCHEMBL9058899 | 0.97 | CYP1A2 (0.61) | — | |
| SCHEMBL812920 | 0.95 | CYP1A2 (0.71) | — | |
| SCHEMBL94068 | 0.92 | CYP1A2 (0.75) | — | |
| SCHEMBL5313692 | 0.92 | CYP1A2 (0.75) | — | |
| SCHEMBL10939618 | 0.92 | CYP1A2 (0.75) | — | |
| Hydrochloric Acid SCHEMBL1720619 | 0.92 | CYP1A2 (0.68) | — | |
| SCHEMBL8202520 | 0.90 | CYP1A2 (0.72) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021202781-A1 | N-HETEROARYLALKYL-2-(HETEROCYCLYL AND HETEROCYCLYLMETHYL) ACETAMIDE DERIVATIVES AS SSTR4 AGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-10-07 | — | — | WO | disclosed |
| US-10233446-B2 | Micro-RNA inhibitor | BONAC CORPORATION (JP) | 2019-03-19 | — | — | US | disclosed |
| US-20160311823-A1 | SYNTHETIC VOACANGINE | DEMERX, INC. (US) | 2016-10-27 | — | — | US | disclosed |
| US-9469649-B2 | Synthetic voacangine | DEMERX, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-20150094466-A1 | SYNTHETIC VOACANGINE | DEMERX, INC. (US) | 2015-04-02 | — | — | US | disclosed |
| US-8877921-B2 | Synthetic voacangine | DEMERX, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20130211073-A1 | SYNTHETIC VOACANGINE | DEMERX, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| EP-2247293-A2 | NOVEL COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES RELATED TO ACTIVATED LYMPHOCYTES | Immune Control, Inc. (US) | 2010-11-10 | — | — | EP | disclosed |
| US-20090275557-A1 | Novel Composition for Treatment of Diseases Related to Activated Lymphocytes | IMMUNE CONTROL, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| WO-2009108635-A2 | NOVEL COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES RELATED TO ACTIVATED LYMPHOCYTES | IMMUNE CONTROL, INC. (US) | 2009-09-03 | — | — | WO | disclosed |
| EP-1062360-A1 | COMPOSITIONS AND METHODS FOR ENHANCED SYNTHESIS OF NUCLEIC ACID MOLECULES | Life Technologies, Inc. (US) | 2000-12-27 | — | — | EP | disclosed |
| WO-1999046400-A9 | COMPOSITIONS AND METHODS FOR ENHANCED SYNTHESIS OF NUCLEIC ACID MOLECULES | LIFE TECHNOLOGIES INC (US) | 2000-02-03 | — | — | WO | disclosed |
| WO-1999046400-A1 | COMPOSITIONS AND METHODS FOR ENHANCED SYNTHESIS OF NUCLEIC ACID MOLECULES | LIFE TECHNOLOGIES, INC. (US) | 1999-09-16 | — | — | WO | disclosed |